Alice Ordean

Dr. Alice Ordean

Department of Family Medicine, St Joseph's Health Centre, Toronto, Ontario, Canada
+2
orcid
MD, CCFP(AM), MHSc, FCFP, FASAM

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
Alice OrdeanAlice Ordean
Alice Ordean
SWSuzanne Wong
Suzanne Wong
LGLisa Graves
Lisa Graves

1 October 2020 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
Alice OrdeanAlice Ordean
Alice Ordean
GKGloria Kim
Gloria Kim

1 March 2015 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
Alice OrdeanAlice Ordean
Alice Ordean
MKMeldon Kahan
Meldon Kahan
LGLisa Graves
Lisa Graves
RARon Abrahams
Ron Abrahams
TKTheresa Kim
Theresa Kim

11 February 2023 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Alice OrdeanAlice Ordean
Alice Ordean
MTMeara Tubman-Broeren
Meara Tubman-Broeren
The prevalence of opioid use among pregnant people has been increasing over the past few decades, with a parallel increase in the rate of neonatal abstinence syndrome. Opioid agonist treatment (OAT) including methadone and buprenorphine is the recommended management method for opioid use disorders during pregnancy. Methadone has been extensively studied during pregnancy; however, buprenorphine was introduced in the early 2000s with limited data on the use of different preparations during pregnancy. Buprenorphine-naloxone has been incorporated into routine practice; however, only a few studies have investigated the use of this medication during pregnancy. To determine the safety and efficacy of this medication, we conducted a systematic review of maternal and neonatal outcomes among buprenorphine-naloxone-exposed pregnancies. The primary outcomes of interest were birth parameters, congenital anomalies, and severity of neonatal abstinence syndrome. Secondary maternal outcomes included the OAT dose and substance use at delivery. Seven studies met the inclusion criteria. Buprenorphine-naloxone doses ranged between 8 and 20 mg, and there was an associated reduction of opioid use during pregnancy. There were no significant differences in gestational age at delivery, birth parameters, or prevalence of congenital anomalies between buprenorphine-naloxone-exposed neonates and those exposed to methadone, buprenorphine monotherapy, illicit opioids, or no opioids. In studies comparing buprenorphine-naloxone to methadone, there were reduced rates of neonatal abstinence syndrome requiring pharmacotherapy. These studies demonstrate that buprenorphine-naloxone is a safe and effective opioid agonist treatment for pregnant people with OUD. Further large-scale, prospective data collection is required to confirm these findings. Patients and clinicians may be reassured about the use of buprenorphine-naloxone during pregnancy.

7 November 2019 in Journal of Addiction Medicine
Verified
Journal Article
Open access
Alice OrdeanAlice Ordean
Alice Ordean
MFMilena Forte
Milena Forte
PSPeter Selby
Peter Selby
EGErin Grennell
Erin Grennell
Objectives: Prenatal alcohol and cigarette smoking are associated with numerous adverse pregnancy outcomes. Screening, Brief Intervention, and Referral to Treatment (SBIRT) represents a standardized approach; however, implementation in routine pregnancy care remains a challenge. The purpose of the study was to determine current practices, barriers to implementation, and education needs of healthcare providers utilizing SBIRT to address prenatal alcohol and cigarette smoking. Methods: We conducted a survey of 118 providers including family physicians, midwives, and obstetricians practicing at 2 Toronto hospitals: community-based teaching site and fully affiliated academic health sciences center. Results: The response rate was 79%. Almost all providers reported screening every pregnant woman for alcohol and smoking status. Brief intervention was offered by fewer providers. Education and supportive counseling were reported by a higher percentage of providers for prenatal cigarette smoking in comparison to alcohol use. Furthermore, up to 60% referred pregnant women to treatment programs for alcohol and cigarette smoking. A significantly higher number of community-based providers reported referring pregnant women to addiction treatment programs. Barriers to interventions included a perceived lack of appropriate resources, training, and clinical pathways. Conclusion: Healthcare providers report universal screening for prenatal alcohol and cigarette smoking; however, brief intervention and referral to treatment are more limited practices. There is a need for education of all providers regarding effective brief counseling strategies and referral to appropriate treatment resources. Development of clinical care pathways may also increase adoption of all components of SBIRT for prenatal alcohol use and cigarette smoking.

1 May 2007 in Substance Abuse
Verified
Journal Article
Closed access
LLL. G. Lefebvre
L. G. Lefebvre
Alice OrdeanAlice Ordean
Alice Ordean
DMD. Midmer
D. Midmer
MKM. Kahan
M. Kahan
GTG. Tolomiczenko
G. Tolomiczenko
Objective: To assess: (1) physicians’ knowledge and clinical confidence regarding problematic substance use in pregnancy compared to folic acid, and (2) physicians’ desire for education in this area and their preferred learning modalitiestools. Design: Self-administered survey. Setting: Family Medicine Forum 2004 in Toronto, Canada. Participants: Physicians attending Family Medicine Forum2004 in Toronto who provide antenatal care. Main Outcome Measures: Knowledge of folic acid, smoking and alcohol in pregnancy. Clinical confidence and interest in resources regarding problematic substance use in pregnancy. Results: Sixty-six surveys completed. Physicians answered 92.3% of folic acid questions correctly, compared to 82.0% for nicotine and 57.1% for alcohol. Scores were higher on questions about effects of nicotine and alcohol use in pregnancy than on questions about treatment options. A perceived inability to influence clinical outcomes and a lack of professional resources regarding substance use in pregnancy were also identified. Physicians were interested in learning more about problematic substance use in pregnancy, particularly from continuing medical education events, websites and pocket cards. Conclusion: Participants’ level of knowledge regarding substance use in pregnancy was significantly lower than their knowledge of folic acid, as was their clinical confidence. This lack of knowledge was not attributable to disinterest and clearly more educational resources are needed to address this topic.